^
Association details:
| Biomarker: | HLA-A*02 + PD-L1 expression |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | MT-6402 (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.
Published date:
05/31/2023
Excerpt:
Dose escalation continues with MT-6402 (QW in 4-week cycles) in pts with relapsed/refractory PD-L1+ solid tumors...MT-6402 utilizes three PD-L1-targeted and unique MOAs: direct cell-kill, reduced immunosuppression, and increased immunorecognition…A PR in 1 pt with CPI-refractory NPC (CPS 2%, CMV-) and regression of osseous metastases in a pt...(TPS 80%, HLA-A*02/CMV+) following disease progression on CPI occurred...These results show MT-6402 monotherapy activity though unique MOAs and provide rationale for MT-6402 dose expansion.
DOI:
10.1200/JCO.2023.41.16_suppl.2552
Trial ID:
Source:
Title:
764 First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: interim data FREE
Published date:
11/07/2022
Excerpt:
These results describe a novel approach to checkpoint modulation by MT-6402 with a potential to alter tumor immunophenotype particularly in patients with HLA-A*02/CMV positivity. Dose escalation is ongoing. These results provide compelling rationale for continued development of MT-6402, including in the R/R setting...
DOI:
10.1136/jitc-2022-SITC2022.0764
Trial ID:
